Soleus Capital Master Fund, L.P. - 30 Jun 2025 SCHEDULE 13G/A Report for UROGEN PHARMA LTD. Ordinary Shares, par value NIS 0.01 per share (URGN)

Filing Manager
Soleus Capital Master Fund, L.P.
Reporting Manager
Soleus Capital Master Fund, L.P.
Security
UROGEN PHARMA LTD. Ordinary Shares, par value NIS 0.01 per share
Symbol
URGN
Shares outstanding
46,489,362 shares
Disclosed Ownership
2,185,000 shares
Ownership
4.7%
Form type
SCHEDULE 13G/A
Filing time
05 Aug 2025, 17:00:03 UTC
Date of event
30 Jun 2025
Previous filing
16 Jun 2025
SEC
View on sec.gov

Quoteable Key Fact

"Soleus Capital Master Fund, L.P. disclosed 4.7% ownership in UROGEN PHARMA LTD. Ordinary Shares, par value NIS 0.01 per share (URGN) on 30 Jun 2025."

Quick Takeaways

  • Soleus Capital Master Fund, L.P. filed SCHEDULE 13G/A for UROGEN PHARMA LTD. Ordinary Shares, par value NIS 0.01 per share (URGN).
  • Disclosed ownership: 4.7%.
  • Date of event: 30 Jun 2025.

What Changed

  • Previous schedule filing date: 16 Jun 2025.
  • Current filing was accepted on 05 Aug 2025, 17:00.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Soleus Capital Master Fund, L.P. 4.7% 2,185,000 0 2,185,000 /s/ Guy Levy Guy Levy/Managing Member
Soleus Capital, LLC 4.7% 2,185,000 0 2,185,000 /s/ Guy Levy Guy Levy/Managing Member
Soleus Capital Group, LLC 4.7% 2,185,000 0 2,185,000 /s/ Guy Levy Guy Levy/Managing Member
Soleus Capital Management, L.P. 4.7% 2,185,000 0 2,185,000 /s/ Guy Levy Guy Levy/Managing Member
Soleus GP, LLC 4.7% 2,185,000 0 2,185,000 /s/ Guy Levy Guy Levy/Managing Member
Guy Levy 4.7% 2,185,000 0 2,185,000 /s/ Guy Levy Guy Levy/Individual